top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Jeff Evanson Biography and Net Worth

Insider of Outlook Therapeutics

Mr. Evanson has served as our Chief Commercial Officer since November 2018. Mr. Evanson joined Outlook Therapeutics from Scott Three Consulting where he was the Founder and President. Previously he was a Managing Director in the Life Science Practice of Navigant from 2014 to 2018. He joined the firm in September of 2014 from Novartis (Alcon) where he was the Vice President and Global Commercial Head of the Pharmaceutical Franchise. During his time at Alcon, he was responsible for all aspects of strategy, portfolio (both internal and external opportunities), global brands, launches and campaigns. Mr. Evanson has extensive experience with the ophthalmology and retina landscape including sustained delivery, drug/device combination and diagnostics within the dry eye, glaucoma, retina and allergy eye health markets.

Prior to Novartis, Mr. Evanson spent 10 years at Medtronic in a variety of pre-commercialization and post-commercialization roles. He has led programs from Opportunity Assessment through to Global Launch Plans and Life Cycle Management. These responsibilities allowed Mr. Evanson direct experience with the US FDA and the US Centers for Medicare and Medicaid Services. Mr. Evanson also has experience in Pharmaceutical Sales and Sales Training.

Jeff received his MBA from the University of Minnesota (2001) and a BA in Chemistry from the University of St. Thomas in St. Paul Minnesota (1991). He served as a two-term Board Member of Gillette Children’s Hospital in St. Paul, Minnesota, from 2008 to 2014 and currently is on the Board of Directors of Children’s HeartLink.

What is Jeff Evanson's net worth?: The estimated net worth of Jeff Evanson is at least $421,897.84 as of January 19th, 2023. Mr. Evanson owns 50,648 shares of Outlook Therapeutics stock worth more than $421,898 as of April 23rd. This net worth evaluation does not reflect any other investments that Mr. Evanson may own. Additionally, Mr. Evanson receives an annual salary of $451,170.00 as Insider at Outlook Therapeutics. Learn More about Jeff Evanson's net worth.
How old is Jeff Evanson?: Mr. Evanson is currently 55 years old. There are 3 older executives and no younger executives at Outlook Therapeutics. The oldest executive at Outlook Therapeutics is Mr. Ralph H. Thurman, Independent Executive Chairman, who is 75 years old. Learn More on Jeff Evanson's age.
What is Jeff Evanson's salary?: As the Insider of Outlook Therapeutics, Inc., Mr. Evanson earns $451,170.00 per year. The highest earning executive at Outlook Therapeutics is Mr. C. Russell Trenary III, President, CEO & Director, who commands a salary of $610,900.00 per year. Learn More on Jeff Evanson's salary.
How do I contact Jeff Evanson?: The corporate mailing address for Mr. Evanson and other Outlook Therapeutics executives is 4260 U.S. ROUTE 1, MONMOUTH JUNCTION NJ, 08852. Outlook Therapeutics can also be reached via phone at (609) 619-3990 and via email at [email protected]. Learn More on Jeff Evanson's contact information.
Has Jeff Evanson been buying or selling shares of Outlook Therapeutics?: Jeff Evanson has not been actively trading shares of Outlook Therapeutics during the last quarter. Most recently, Jeff Evanson sold 5,162 shares of the business's stock in a transaction on Thursday, January 19th. The shares were sold at an average price of $24.40, for a transaction totalling $125,952.80. Following the completion of the sale, the insider now directly owns 50,648 shares of the company's stock, valued at $1,235,811.20. Learn More on Jeff Evanson's trading history.
Who are Outlook Therapeutics' active insiders?: Outlook Therapeutics' insider roster includes Terry Dagnon (COO), Jeff Evanson (Insider), Yezan Haddadin (Director), Ghiath Sukhtian (Director), and C Trenary, III (CEO). Learn More on Outlook Therapeutics' active insiders.
Are insiders buying or selling shares of Outlook Therapeutics?: In the last year, Outlook Therapeutics insiders bought shares 1 times. They purchased a total of 1,882 shares worth more than $22,245.24. The most recent insider tranaction occured on March, 28th when Director Yezan Munther Haddadin bought 1,882 shares worth more than $22,245.24. Insiders at Outlook Therapeutics own 5.3% of the company. Learn More about insider trades at Outlook Therapeutics.
Information on this page was last updated on 3/28/2024.

Jeff Evanson Insider Trading History at Outlook Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/19/2023	Sell	5,162	$24.40	$125,952.80	50,648
1/17/2023	Sell	1,358	$26.20	$35,579.60	57,498
12/3/2021	Buy	1,760	$26.80	$47,168.00
2/23/2021	Sell	427	$41.80	$17,848.60	57,096
2/12/2021	Sell	2,848	$51.00	$145,248.00	57,524

Jeff Evanson Buying and Selling Activity at Outlook Therapeutics

Outlook Therapeutics Company Overview

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Today's Range

Now: $8.28

$8.15

$8.44

50 Day Range

MA: $8.59

$5.73

$11.94

2 Week Range

Now: $8.28

$4.00

$40.60

Volume

76,572 shs

Average Volume

536,713 shs

Market Capitalization

$107.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.04

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Jeff Evanson Biography and Net Worth

What is Jeff Evanson's net worth?

How old is Jeff Evanson?

What is Jeff Evanson's salary?

How do I contact Jeff Evanson?

Has Jeff Evanson been buying or selling shares of Outlook Therapeutics?

Who are Outlook Therapeutics' active insiders?

Are insiders buying or selling shares of Outlook Therapeutics?